TCTMD: ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

Saint Luke's Mid America Heart Institute is proud to have played a major role in the largest-ever randomized international trial to compare initial invasive surgical treatment vs. managing with medication and lifestyle changes for stable ischemic heart disease. The ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial focused on evaluating survival and benefits to the patients quality of life.

“In patients with angina, shared decision-making should occur to align treatment with patients’ goals and preferences,” said Dr. John Spertus, director of health outcomes research at Saint Luke's Mid America Heart Institute and co-principal investigator for the ISCHEMIA quality of life analysis. 

Read the full article from TCTMD: ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

Related Content

stethoscope laying on of of data sheets with computer and physician hands on keyboard with research and data points
Mar. 30, 2020

NIH-funded studies show stents and surgery no better than medication, lifestyle changes at reducing cardiac events
Saint Luke's Director of Health Outcomes and Research at Saint Luke's Mid America Heart Institute helps in NIH-funded studies that find stents, surgery provide higher quality of life for those with chest pain.
doctor taking patients blood pressure
Nov. 18, 2019

Saint Luke’s Mid America Heart Institute is a major participant in international "practice-changing" clinical trial for patients with ischemic heart disease
ISCHEMIA trial outcomes found a significant benefit in quality of life and patient experience.

John A Spertus, MD

Cardiology